Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial

IMPORTANCE: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2–positive breast cancer, by modulating antibody-dependent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Gavin, Patrick G., Song, Nan, Kim, S. Rim, Lipchik, Corey, Johnson, Nicole L., Bandos, Hanna, Finnigan, Melanie, Rastogi, Priya, Fehrenbacher, Louis, Mamounas, Eleftherios P., Swain, Sandra M., Wickerham, D. Lawrence, Geyer, Charles E., Jeong, Jong-Hyeon, Costantino, Joseph P., Wolmark, Norman, Paik, Soonmyung, Pogue-Geile, Kay L.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344747/
https://ncbi.nlm.nih.gov/pubmed/27812689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.4884
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars